Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across IndiaJune 18, 2025
Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – OncologyMay 29, 2025
Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment WebinarMay 22, 2025
Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15, 2025